899 filings
8-K
ADXS
Ayala Pharmaceuticals, Inc.
22 Dec 20
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard
4:43pm
8-K
ADXS
Ayala Pharmaceuticals, Inc.
27 Nov 20
Advaxis, Inc. Announces Closing of $9.2 Million Public Offering
4:34pm
424B5
ADXS
Ayala Pharmaceuticals, Inc.
24 Nov 20
Prospectus supplement for primary offering
5:30pm
8-K
ADXS
Ayala Pharmaceuticals, Inc.
24 Nov 20
Advaxis, Inc. Announces Pricing of $8 Million Public Offering
8:30am
424B5
ADXS
Ayala Pharmaceuticals, Inc.
23 Nov 20
Prospectus supplement for primary offering
4:27pm
8-K
3yp 50t72ifs0
23 Nov 20
Advaxis, Inc. Announces Proposed Public Offering of
4:25pm
8-K
u9wzr9cbv 9m7g9musp
16 Oct 20
Entry into a Material Definitive Agreement
5:05pm
8-K
s1izqgjysoowso7
8 Oct 20
Termination of a Material Definitive Agreement
7:00am
8-A12B
xisictdj6
29 Sep 20
Registration of securities on exchange
9:08am
8-K
usmcvrb2mi43w2drnejw
29 Sep 20
Entry into a Material Definitive Agreement
8:59am
8-K
n1h3wpxbi2 c6x3r7
10 Sep 20
Strategic expansion of ADXS-503 HOT program in NSCLC to explore potential to enhance and or restore sensitivity to checkpoint inhibitors
4:00pm
8-K
zmi6u9zb2nfaharc 7y
4 Sep 20
Advaxis Announces Resignation of Chief Financial Officer
4:35pm
SC 13G
wz7l9mq2
3 Aug 20
Advaxis / Lincoln Park Capital Fund ownership change
4:03pm
424B5
qkp2ko9r vcm82qc
3 Aug 20
Prospectus supplement for primary offering
8:08am
8-K
0epcxc
3 Aug 20
Advaxis Announces Common Stock Purchase Agreement for up to $20 Million with Lincoln Park Capital
8:05am
S-8
kjwaf
26 Jun 20
Registration of securities for employees
4:05pm
424B5
23l6tyw85tkpigc
8 May 20
Prospectus supplement for primary offering
4:08pm
8-K
l17 8yroq
8 May 20
Entry into a Material Definitive Agreement
4:05pm